GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Society of Hematology  (4)
  • 1
    Online Resource
    Online Resource
    American Society of Hematology ; 2007
    In:  Blood Vol. 110, No. 10 ( 2007-11-15), p. 3489-3489
    In: Blood, American Society of Hematology, Vol. 110, No. 10 ( 2007-11-15), p. 3489-3489
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2007
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Blood, American Society of Hematology, Vol. 120, No. 20 ( 2012-11-15), p. 4229-4237
    Abstract: A nitric oxide synthase (NOS)–like activity has been demonstrated in human red blood cells (RBCs), but doubts about its functional significance, isoform identity and disease relevance remain. Using flow cytometry in combination with the nitric oxide (NO)–imaging probe DAF-FM we find that all blood cells form NO intracellularly, with a rank order of monocytes 〉 neutrophils 〉 lymphocytes 〉 RBCs 〉 platelets. The observation of a NO-related fluorescence within RBCs was unexpected given the abundance of the NO-scavenger oxyhemoglobin. Constitutive normoxic NO formation was abolished by NOS inhibition and intracellular NO scavenging, confirmed by laser-scanning microscopy and unequivocally validated by detection of the DAF-FM reaction product with NO using HPLC and LC-MS/MS. Using immunoprecipitation, ESI-MS/MS-based peptide sequencing and enzymatic assay we further demonstrate that human RBCs contain an endothelial NOS (eNOS) that converts L-3H-arginine to L-3H-citrulline in a Ca2+/calmodulin-dependent fashion. Moreover, in patients with coronary artery disease, red cell eNOS expression and activity are both lower than in age-matched healthy individuals and correlate with the degree of endothelial dysfunction. Thus, human RBCs constitutively produce NO under normoxic conditions via an active eNOS isoform, the activity of which is compromised in patients with coronary artery disease.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2012
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Blood, American Society of Hematology, Vol. 104, No. 11 ( 2004-11-16), p. 238-238
    Abstract: Several groups have recently shown that blood can transport nitric oxide (NO) bioactivity so that NO can act as an endocrine signal transducer. The mechanisms of this process are uncertain. We have recently shown that nitrite ions can generate NO in the presence of deoxygenated hemoglobin (Cosby et al. Nature Medicine 2003). Thus, nitrite appears to be a major intravascular NO storage molecule and hemoglobin a nitrite reductase contributing to erythrocyte-dependent hypoxic vasodilation. Such a model requires a reaction of nitrite with intra-erythrocytic hemoglobin, however, published uptake rates of nitrite from plasma into erythrocytes are very slow and dynamic blood flow regulation requires more rapid responses. We therefore hypothesized that the red blood cell itself might be a reservoir for nitrite, with compartmentalization of nitrite and deoxyhemoglobin at the erythrocyte membrane; such a metabolon would allow for rapid nitrite reductase chemistry and NO export as hemoglobin deoxygenates. Nitrite was measured using reductive chemiluminescence in conjunction with a novel ferricyanide-based hemoglobin oxidation assay to rapidly preserve nitrite in the presence of hemoglobin following red cell lysis. We find that measurement of whole blood nitrite using ferricyanide-based hemoglobin oxidation to stabilize nitrite is a valid, sensitive, linear, and reproducible surrogate for RBC nitrite. Using the stabilization solution, nitrite in whole blood remained constant over 12 h at room temperature, whereas without it the half life of nitrite was 12 ± 4 min. Using this novel methodology, the nitrite levels measured in plasma, RBC, and calculated and measured in whole blood in normal volunteers were 121 ± 9, 620 ± 170, 245 ± 58, and 323 ± 44 nmol/L. The difference between measured and calculated blood nitrite levels reflects destruction of RBC nitrite by hemoglobin during sample processing. There was an artery-to-vein gradient for blood nitrite (A. vs V.: 169 ± 12 vs. 149 ± 11 nmol/L; p=0.03). Intraperitoneal injection of L-NAME (a potent NOS-inhibitor; 100 mg/kg) in mice caused a time dependent decrease of whole blood nitrite (0 h: 650 ± 29, 2h: 556 ± 26, 4h: 455 ± 11, 421 ± 19, 24 h: 551 ± 30 nmol/L; p=0.002). Differences of blood nitrite across the human forearm circulation correlated significantly (r2=0.94) with forearm bloodflow after infusion of acetylcholine (7.5 ug/min; n=5), consistent with nitrite formation across the vasculature with eNOS activation. We conclude that in humans, the RBC nitrite concentration is 5 times greater than plasma nitrite concentrations; A-V gradients in blood nitrite are consistent with nitrite utilization as a source of bioactive NO in the microvasculature and levels of blood nitrite are controlled by endogenous NO production. Levels of nitrite in the RBC may function as a locally available source of nitrite for deoxyhemoglobin-dependent nitrite reduction to NO, thus allowing for more efficient nitrite-deoxyhemoglobin mediated hypoxic vasodilation. Modulation of intraerythrocytic nitrite may be of therapeutic interest in diseases with a lack of bioavailable NO, such as sickle cell disease.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2004
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Blood, American Society of Hematology, Vol. 108, No. 11 ( 2006-11-16), p. 3678-3678
    Abstract: Background and Aims: The role of intensive care unit (ICU) support for patients following allogeneic peripheral blood stem cell transplantation (PBSCT) is controversial. In an era of constrained resources, we assessed prognostic factors predictive for survival in patients after myeloablative (MAC) and non-myeloablative allogeneic (non-MAC) PBSCT over a period of seven years. Patients: Between January 1999 and February 2006 three-hundred and one patients with various hematological malignancies underwent allogeneic stem cell tranplantation in our institution (MAC 196, non-MAC 105). Of these, sixty-four patients (21,3%) with a median age of 47 years (range 18–64 years; female 24, male 40; MAC 49, non-MAC 15) were admitted to the ICU during the first two years following PBSCT (median 55 days, range 1–631 days). We looked for variables defining the SOFA (Sequential Organ Failure Assessment) and the SAPS (Simplified Acute Physiology Score) score on the day of ICU admission and five days later to discriminate patients with poor and good prognosis with regard to survival. We also looked for variables such as age of patients, diagnosis, disease status, donor type, time between transplantation and ICU admission, reason for ICU admission and occurrence of veno-occlusive disease and GVHD. Results: Mechanical ventilation was required by all patients admitted to the ICU. Median survival following referral to ICU was 22 days (range 0 – 959 days). The main reason for death was sepsis (56%). Among 49 patients who had received MAC 19 (39%) survived the ICU stay with a median survival time of 11 months (range 0–29 months). In the group of patients who had received non-MAC 3 out of 15 patients (20%) could be discharged from the ICU with a median survival time of 5 months (range 4–12 months). Looking at the twenty-two ICU survivors there were seven patients who survived the following year resulting in an overall survival of 11% one year after ICU admission. Only the SOFA score (p = 0.002) on the day of ICU admission was of prognostic relevance for survival. Conclusion: ICU admission and respiratory failure are associated with poor prognosis after allogeneic stem cell transplantation The probability of survival is independent from the type of conditioning therapy. The SOFA score is a predictor for short term survival but fails to identify long term survivors.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2006
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...